Vijay Maruti Patil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vijay Maruti Patil has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
- Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400012, India
18 shared publications - Vanita Noronha
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India
12 shared publications - Nandini Menon
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India
9 shared publications - Atanu Bhattacharjee
University of Dundee
8 shared publications Nandini Menon
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
7 shared publicationsRakesh Jalali
Department of Radiation Oncology, Apollo Proton Cancer Center, Chennai, Tamil Nadu, India
7 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Wolters Kluwer Health in Cancer Research, Statistics, and Treatment
- Vol. 9 (4) , 179-187
Compliance, toxicity and quality of life in a Phase 3 randomized trial of adjuvant temozolomide versus PCV in grade 2–3 gliomas
Background: Procarbazine, lomustine, vincristine (PCV) and temozolomide (TMZ) are adjuvant therapy options for grade 2 and 3 gliomas. We report compliance, toxicity, and quality of life (QoL) outcomes from an ongoing study comparing these regimens. Objectives: The primary objective was to determine whether adjuvant TMZ is noninferior to PCV in terms of progression-free survival. Secondary objectives were to compare compliance, toxicity, and QoL between the two regimens. Materials and Methods: Adults with high-risk gra: de 2 or 3 gliomas were randomized (2:1) to receive TMZ or PCV after radiotherapy. The TMZ arm received concurrent TMZ (75 mg/m 2 /day) followed by adjuvant TMZ (150-200 mg/m 2 , days 1-5 every 28 days, up to 12 cycles). The PCV arm received procarbazine (60 mg/m 2 , days 8-21), lomustine (110 mg/m 2 , day 1), and vincristine (1.4 mg/m 2 , days 8 and 29) every 56 days for up to 6 cycles. Results: This analysis included the first 50 patients (TMZ, n = 32; PCV, n = 18). Two patients in each arm did not initiate adjuvant chemotherapy. Chemotherapy completion rates were higher with TMZ (86.7%, n = 26) than PCV (68.8%, n = 11). Dose reductions were significantly more frequent with PCV (68.8%, n = 11 vs 3.3%, n = 1; P < 0.001). Grade ≥3 anemia ( P , 0.011), neutropenia ( P , 0.001), thrombocytopenia ( P , 0.015), and lymphopenia ( P < 0.001) were significantly higher with PCV. QoL did not differ significantly between arms. Conclusion: Adjuvant PCV is feasible with careful monitoring, although it is associated with higher toxicity than TMZ.
- 9 September 2026
- Published by Wolters Kluwer Health in Cancer Research, Statistics, and Treatment
- Vol. 9 (4) , 179-187
Open AccessCompliance, toxicity and quality of life in a Phase 3 randomized trial of adjuvant temozolomide versus PCV in grade 2–3 gliomas
Background: Procarbazine, lomustine, vincristine (PCV) and temozolomide (TMZ) are adjuvant therapy options for grade 2 and 3 gliomas. We report compliance, toxicity, and quality of life (QoL) outcomes from an ongoing study comparing these regimens. Objectives: The primary objective was to determine whether adjuvant TMZ is noninferior to PCV in terms of progression-free survival. Secondary objectives were to compare compliance, toxicity, and QoL between the two regimens. Materials and Methods: Adults with high-risk gra: de 2 or 3 gliomas were randomized (2:1) to receive TMZ or PCV after radiotherapy. The TMZ arm received concurrent TMZ (75 mg/m 2 /day) followed by adjuvant TMZ (150-200 mg/m 2 , days 1-5 every 28 days, up to 12 cycles). The PCV arm received procarbazine (60 mg/m 2 , days 8-21), lomustine (110 mg/m 2 , day 1), and vincristine (1.4 mg/m 2 , days 8 and 29) every 56 days for up to 6 cycles. Results: This analysis included the first 50 patients (TMZ, n = 32; PCV, n = 18). Two patients in each arm did not initiate adjuvant chemotherapy. Chemotherapy completion rates were higher with TMZ (86.7%, n = 26) than PCV (68.8%, n = 11). Dose reductions were significantly more frequent with PCV (68.8%, n = 11 vs 3.3%, n = 1; P < 0.001). Grade ≥3 anemia ( P , 0.011), neutropenia ( P , 0.001), thrombocytopenia ( P , 0.015), and lymphopenia ( P < 0.001) were significantly higher with PCV. QoL did not differ significantly between arms. Conclusion: Adjuvant PCV is feasible with careful monitoring, although it is associated with higher toxicity than TMZ.
- 24 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Randomized trial of adjuvant 5-FU-platinum versus paclitaxel-platinum for high-risk penile cancer
Background: Adjuvant chemotherapy is recommended for high-risk penile squamous cell carcinoma (SCC) metastatic to lymph nodes based on retrospective data, but no randomized trials have been conducted. We compared 5-fluorouracil (5-FU)-platinum with paclitaxel-platinum in this setting. Methods: In this open-label, randomized trial at an Indian tertiary cancer center, men 1 inguinal nodes, or ≥4 cm node) were assigned 1:1 to four 3-weekly cycles of 5-FU-platinum or paclitaxel-platinum, followed by cisplatin-based chemoradiotherapy. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS), toxicity, and quality-of-life (QoL). Results: Between 2017 and 2024, 49 patients were randomized (5-FU-platinum: 25, paclitaxel-platinum: 24). At a median follow-up of 69 months, median DFS was 12.4 months (95% CI = 3.38 to not reached [NR]) vs 19.6 months (95% CI = 5.82 to NR) (HR = 1.16; 95% CI = 0.55 to 2.45; P = .686), and median OS was 21.3 vs 36.7 months (HR = 1.13; 95% CI = 0.52 to 2.44; P = .754) for 5-FU-platinum and paclitaxel-platinum, respectively. Grade ≥3 toxicities occurred in 77.3% vs 40.9% (P = .014), grade ≥3 hematologic toxicities in 54.5% vs 4.5% (P < .001), and hospitalization for toxicity in 45.5% vs 9.1% (P = .016). Completion of all planned cycles was higher with paclitaxel-platinum (83.3% vs 48%; P = .009). QoL and sexual health were similar between the 2 treatment arms. Conclusions: Adjuvant paclitaxel-platinum was associated with improved tolerability compared with fluorouracil-platinum in high-risk node-positive penile cancer and warrants further evaluation in larger multicenter studies. Early termination precluded definitive efficacy comparisons. Trial registration: Clinical Trials Registry of India (CTRI/2016/12/007567).
- 24 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Randomized trial of adjuvant 5-FU-platinum versus paclitaxel-platinum for high-risk penile cancer
Background: Adjuvant chemotherapy is recommended for high-risk penile squamous cell carcinoma (SCC) metastatic to lymph nodes based on retrospective data, but no randomized trials have been conducted. We compared 5-fluorouracil (5-FU)-platinum with paclitaxel-platinum in this setting. Methods: In this open-label, randomized trial at an Indian tertiary cancer center, men 1 inguinal nodes, or ≥4 cm node) were assigned 1:1 to four 3-weekly cycles of 5-FU-platinum or paclitaxel-platinum, followed by cisplatin-based chemoradiotherapy. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS), toxicity, and quality-of-life (QoL). Results: Between 2017 and 2024, 49 patients were randomized (5-FU-platinum: 25, paclitaxel-platinum: 24). At a median follow-up of 69 months, median DFS was 12.4 months (95% CI = 3.38 to not reached [NR]) vs 19.6 months (95% CI = 5.82 to NR) (HR = 1.16; 95% CI = 0.55 to 2.45; P = .686), and median OS was 21.3 vs 36.7 months (HR = 1.13; 95% CI = 0.52 to 2.44; P = .754) for 5-FU-platinum and paclitaxel-platinum, respectively. Grade ≥3 toxicities occurred in 77.3% vs 40.9% (P = .014), grade ≥3 hematologic toxicities in 54.5% vs 4.5% (P < .001), and hospitalization for toxicity in 45.5% vs 9.1% (P = .016). Completion of all planned cycles was higher with paclitaxel-platinum (83.3% vs 48%; P = .009). QoL and sexual health were similar between the 2 treatment arms. Conclusions: Adjuvant paclitaxel-platinum was associated with improved tolerability compared with fluorouracil-platinum in high-risk node-positive penile cancer and warrants further evaluation in larger multicenter studies. Early termination precluded definitive efficacy comparisons. Trial registration: Clinical Trials Registry of India (CTRI/2016/12/007567).
- Open Access
Decoding Osteoradionecrosis of the Jaw: Radiological Progression and a Novel CT-Based Grading System
Background: Osteoradionecrosis (ORN) of the jaw is a severe, progressive complication of radiation therapy for head and neck malignancies. ORN features radiologically overlaps osteomyelitis and tumor recurrence. This study analyzes jaw ORN imaging characteristics and progression and proposes an ORN CT-based grading system that builds on current ClinRAD grades. Materials and Methods: A retrospective cohort study of 35 patients with biopsy-proven or clinically diagnosed ORN following radiation therapy. Initial and follow-up imaging were assessed to evaluate the radiological evolution of ORN. The imaging findings were statistically analyzed using IBM SPSS v26, and literature comparisons were made. Results: The median onset of ORN post-radiotherapy was 27–28 months (range: 2–119 months). The most common clinical presentations included non-healing ulcers (49%), pain (34%), and discharging sinuses (31%). Mandibular involvement was predominant (51%), with focal bone alterations being more frequent (63%). CT findings at clinical suspicion of ORN included resorption (100%), erosions (100%), sclerosis (86%), and fragmentation (83%). Follow-up imaging showed increased bone erosion (77%), fragmentation (92%), and sclerosis (92%). A CT-based grading system is proposed to classify ORN progression. Conclusions: ORN follows a predictable radiological progression, beginning with trabecular resorption and cortical erosion, leading to fragmentation and sequestrum formation. The proposed grading system provides a structured approach for early diagnosis. The proposed grading system provides a structured approach for diagnosis. Larger studies of imaging analyses are required to validate these findings and refine diagnostic criteria.
Open AccessDecoding Osteoradionecrosis of the Jaw: Radiological Progression and a Novel CT-Based Grading System
Background: Osteoradionecrosis (ORN) of the jaw is a severe, progressive complication of radiation therapy for head and neck malignancies. ORN features radiologically overlaps osteomyelitis and tumor recurrence. This study analyzes jaw ORN imaging characteristics and progression and proposes an ORN CT-based grading system that builds on current ClinRAD grades. Materials and Methods: A retrospective cohort study of 35 patients with biopsy-proven or clinically diagnosed ORN following radiation therapy. Initial and follow-up imaging were assessed to evaluate the radiological evolution of ORN. The imaging findings were statistically analyzed using IBM SPSS v26, and literature comparisons were made. Results: The median onset of ORN post-radiotherapy was 27–28 months (range: 2–119 months). The most common clinical presentations included non-healing ulcers (49%), pain (34%), and discharging sinuses (31%). Mandibular involvement was predominant (51%), with focal bone alterations being more frequent (63%). CT findings at clinical suspicion of ORN included resorption (100%), erosions (100%), sclerosis (86%), and fragmentation (83%). Follow-up imaging showed increased bone erosion (77%), fragmentation (92%), and sclerosis (92%). A CT-based grading system is proposed to classify ORN progression. Conclusions: ORN follows a predictable radiological progression, beginning with trabecular resorption and cortical erosion, leading to fragmentation and sequestrum formation. The proposed grading system provides a structured approach for early diagnosis. The proposed grading system provides a structured approach for diagnosis. Larger studies of imaging analyses are required to validate these findings and refine diagnostic criteria.
- Open Access
- 30 September 2025
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 19
CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how?
CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how? Deevyashali Parekh1, Ansy H Patel1, Areeb Khan1, Eloho Olojakpok
- 30 September 2025
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 19
Open AccessCAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how?
CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how? Deevyashali Parekh1, Ansy H Patel1, Areeb Khan1, Eloho Olojakpok
- 25 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 115802
Response to Letter Re: “A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer”
- 25 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 115802
Response to Letter Re: “A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer”
- 21 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 228, 115730
A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer
- 21 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 228, 115730
A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer
- Open Access
- 26 April 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (1) , 152-157
PD-L1 in Oral Cavity Cancers—Audit for Tertiary Care Center in India
There is no data on the expression of PD-L1 in oral cavity cancers from the Indian population. Hence, this audit was done to estimate the incidence of PD-L1 expression in oral cavity cancers and detect factors affecting the same. Data of 340 cases of oral cavity cancer who were advised for PD-L1 gene expression testing were collected from the head and neck OPD of Tata Memorial Hospital from the year 2018 to 2023. These cases were evaluated for demographic details, i.e., age and gender, and also for factors such as performance status (PS) as per the Eastern Cooperative Oncology Group (ECOG) scale, subsite of oral tumor, histopathology, and grade. Descriptive statistics were used for analysis. Factors affecting PD-L1 gene expression were sorted using ordinal logistic regression analysis. In total, 340 patients were evaluated with a median age of 48 years (range, 17–79; interquartile range, 40–55), and PD-L1 expression was divided as scores and was observed that Tumor Proportion Score (TPS) 0% was seen in 34 patients (10.0%), TPS 1–5% was seen in 70 patients (20.6%), TPS 6–10% was seen in 29 patients (8.5%), TPS 11–20% was seen in 29 patients (8.5%), TPS 21–30% was seen in 33 patients (9.7%), TPS 31–50% was seen in 44 patients (12.9%), TPS 51–75% was seen in 47 patients (13.8%), and TPS > 75% was seen in 54 patients (15.9%). Univariate analysis was run to determine the distribution of TPS scores within each variable under age, gender, sample collection site, differentiation of tumor, and subsite of tumor. This is one of the first studies evaluating data on the expression of PDL-1 in oral cavity cancers in the Indian population and the factors affecting it. The data provides novel insights into many factors potentially affecting the expression of PDL-1 in oral cavity cancers and in the future, can be of help in developing treatment plans with various immunotherapies.
- 26 April 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (1) , 152-157
Open AccessPD-L1 in Oral Cavity Cancers—Audit for Tertiary Care Center in India
There is no data on the expression of PD-L1 in oral cavity cancers from the Indian population. Hence, this audit was done to estimate the incidence of PD-L1 expression in oral cavity cancers and detect factors affecting the same. Data of 340 cases of oral cavity cancer who were advised for PD-L1 gene expression testing were collected from the head and neck OPD of Tata Memorial Hospital from the year 2018 to 2023. These cases were evaluated for demographic details, i.e., age and gender, and also for factors such as performance status (PS) as per the Eastern Cooperative Oncology Group (ECOG) scale, subsite of oral tumor, histopathology, and grade. Descriptive statistics were used for analysis. Factors affecting PD-L1 gene expression were sorted using ordinal logistic regression analysis. In total, 340 patients were evaluated with a median age of 48 years (range, 17–79; interquartile range, 40–55), and PD-L1 expression was divided as scores and was observed that Tumor Proportion Score (TPS) 0% was seen in 34 patients (10.0%), TPS 1–5% was seen in 70 patients (20.6%), TPS 6–10% was seen in 29 patients (8.5%), TPS 11–20% was seen in 29 patients (8.5%), TPS 21–30% was seen in 33 patients (9.7%), TPS 31–50% was seen in 44 patients (12.9%), TPS 51–75% was seen in 47 patients (13.8%), and TPS > 75% was seen in 54 patients (15.9%). Univariate analysis was run to determine the distribution of TPS scores within each variable under age, gender, sample collection site, differentiation of tumor, and subsite of tumor. This is one of the first studies evaluating data on the expression of PDL-1 in oral cavity cancers in the Indian population and the factors affecting it. The data provides novel insights into many factors potentially affecting the expression of PDL-1 in oral cavity cancers and in the future, can be of help in developing treatment plans with various immunotherapies.
- Open Access
- 10 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 99
Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome
Background: According to the 8th edition of the American Joint Committee on Cancer (AJCC), involvement of the masticator space and infratemporal fossa (ITF) in oral cancers indicates advanced disease (T4b), which is often considered unresectable. Previous studies have shown that the extent of ITF involvement influences management and outcomes. Therefore, to optimize management, T4b disease should be subclassified based on ITF involvement. Notably, infranotch disease has a more favorable prognosis compared to supranotch disease. Our study also observed that certain subsets of high anterior retroantral ITF involvement may be operable with favorable clinical outcomes. This study aims to derive a new image-based compartmentalization of high ITF involvement and assess its impact on the management and outcomes of oral head and neck squamous cell carcinoma (HNSCC) patients with high ITF involvement. Materials and Methods: This retrospective observational study included 154 non-metastatic, upfront unresectable locally advanced HNSCC patients who were fit for induction neoadjuvant chemotherapy (NACT). ITF involvement was classified into distinct compartments, and detailed staging of the primary tumor (T) and regional nodes (Ns) was performed. Clinical data, including patient demographics, treatment received, and follow-up notes, were documented. Prognosis was assessed using survival metrics: event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). The ITF was categorized into the following compartments: compartment 1 (low ITF: medial pterygoid), compartment 2 (anterior high ITF: retroantral fat), compartment 3 (posterior high ITF), including 3a (paramandibular compartment: paramandibular fat/temporalis), 3b (muscle compartment: lateral pterygoid), and 3c (Perineural compartment: pterygopalatine fossa and pterygomaxillary fissure). Results: Of the 154 cases, 142 (92%) were classified as T4b, with 63 (40.9%) having high ITF involvement and 79 (55.6%) having low ITF involvement. Twelve cases had T4a disease, which was deemed unresectable due to extensive nodal involvement. Subcompartmentalization of the 63 high ITF cases revealed 26 (41.2%) with compartment 2 involvement, 17 (26.9%) with compartment 3a involvement, 11 (17.4%) with compartment 3b involvement, and 9 (14%) with compartment 3c involvement. Disease progression following NACT was significantly higher in compartment 3c, which showed a poor response (p = 0.007). Univariate analysis for PFS revealed similar outcomes for compartments 1 and 2 (p = 0.692), while compartment 3 demonstrated poorer outcomes (p = 0.033). Among thosehigh ITF involvement, compartment 3c had the worst PFS outcome (p = 0.03). Conclusions: Baseline imaging plays a critical role in guiding individualized treatment and predicting clinical outcomes. Low ITF involvement and disease limited to the high retroantral fat compartment exhibit similar clinical outcomes. Among the posterior high ITF compartments, involvement of the pterygopalatine fossa and pterygomaxillary fissure (compartment 3c) is associated with the worst prognosis and poor response to chemotherapy. Subcompartmentalization of ITF involvement provides valuable prognostic information to tailor treatment strategies.
- 10 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 99
Open AccessCompartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome
Background: According to the 8th edition of the American Joint Committee on Cancer (AJCC), involvement of the masticator space and infratemporal fossa (ITF) in oral cancers indicates advanced disease (T4b), which is often considered unresectable. Previous studies have shown that the extent of ITF involvement influences management and outcomes. Therefore, to optimize management, T4b disease should be subclassified based on ITF involvement. Notably, infranotch disease has a more favorable prognosis compared to supranotch disease. Our study also observed that certain subsets of high anterior retroantral ITF involvement may be operable with favorable clinical outcomes. This study aims to derive a new image-based compartmentalization of high ITF involvement and assess its impact on the management and outcomes of oral head and neck squamous cell carcinoma (HNSCC) patients with high ITF involvement. Materials and Methods: This retrospective observational study included 154 non-metastatic, upfront unresectable locally advanced HNSCC patients who were fit for induction neoadjuvant chemotherapy (NACT). ITF involvement was classified into distinct compartments, and detailed staging of the primary tumor (T) and regional nodes (Ns) was performed. Clinical data, including patient demographics, treatment received, and follow-up notes, were documented. Prognosis was assessed using survival metrics: event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). The ITF was categorized into the following compartments: compartment 1 (low ITF: medial pterygoid), compartment 2 (anterior high ITF: retroantral fat), compartment 3 (posterior high ITF), including 3a (paramandibular compartment: paramandibular fat/temporalis), 3b (muscle compartment: lateral pterygoid), and 3c (Perineural compartment: pterygopalatine fossa and pterygomaxillary fissure). Results: Of the 154 cases, 142 (92%) were classified as T4b, with 63 (40.9%) having high ITF involvement and 79 (55.6%) having low ITF involvement. Twelve cases had T4a disease, which was deemed unresectable due to extensive nodal involvement. Subcompartmentalization of the 63 high ITF cases revealed 26 (41.2%) with compartment 2 involvement, 17 (26.9%) with compartment 3a involvement, 11 (17.4%) with compartment 3b involvement, and 9 (14%) with compartment 3c involvement. Disease progression following NACT was significantly higher in compartment 3c, which showed a poor response (p = 0.007). Univariate analysis for PFS revealed similar outcomes for compartments 1 and 2 (p = 0.692), while compartment 3 demonstrated poorer outcomes (p = 0.033). Among thosehigh ITF involvement, compartment 3c had the worst PFS outcome (p = 0.03). Conclusions: Baseline imaging plays a critical role in guiding individualized treatment and predicting clinical outcomes. Low ITF involvement and disease limited to the high retroantral fat compartment exhibit similar clinical outcomes. Among the posterior high ITF compartments, involvement of the pterygopalatine fossa and pterygomaxillary fissure (compartment 3c) is associated with the worst prognosis and poor response to chemotherapy. Subcompartmentalization of ITF involvement provides valuable prognostic information to tailor treatment strategies.
- Open Access
- 8 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 95
A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging
Background: Precise detection and characterization of pulmonary nodules on computed tomography (CT) is crucial for early diagnosis and management. Objectives: In this study, we propose the use of a deep learning-based algorithm to automatically detect pulmonary nodules in computed tomography (CT) scans. We evaluated the performance of the algorithm against the interpretation of radiologists to analyze the effectiveness of the algorithm. Materials and Methods: The study was conducted in collaboration with a tertiary cancer center. We used a collection of public (LUNA) and private (tertiary cancer center) datasets to train our deep learning models. The sensitivity, the number of false positives per scan, and the FROC curve along with the CPM score were used to assess the performance of the deep learning algorithm by comparing the deep learning algorithm and the radiology predictions. Results: We evaluated 491 scans consisting of 5669 pulmonary nodules annotated by a radiologist from our hospital; our algorithm showed a sensitivity of 90% and with only 0.3 false positives per scan with a CPM score of 0.85. Apart from the nodule-wise performance, we also assessed the algorithm for the detection of patients containing true nodules where it achieved a sensitivity of 0.95 and specificity of 1.0 over 491 scans in the test cohort. Conclusions: Our multi-institutional validated deep learning-based algorithm can aid radiologists in confirming the detection of pulmonary nodules through computed tomography (CT) scans and identifying further abnormalities and can be used as an assistive tool. This will be helpful in national lung screening programs guiding early diagnosis and appropriate management.
- 8 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 95
Open AccessA Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging
Background: Precise detection and characterization of pulmonary nodules on computed tomography (CT) is crucial for early diagnosis and management. Objectives: In this study, we propose the use of a deep learning-based algorithm to automatically detect pulmonary nodules in computed tomography (CT) scans. We evaluated the performance of the algorithm against the interpretation of radiologists to analyze the effectiveness of the algorithm. Materials and Methods: The study was conducted in collaboration with a tertiary cancer center. We used a collection of public (LUNA) and private (tertiary cancer center) datasets to train our deep learning models. The sensitivity, the number of false positives per scan, and the FROC curve along with the CPM score were used to assess the performance of the deep learning algorithm by comparing the deep learning algorithm and the radiology predictions. Results: We evaluated 491 scans consisting of 5669 pulmonary nodules annotated by a radiologist from our hospital; our algorithm showed a sensitivity of 90% and with only 0.3 false positives per scan with a CPM score of 0.85. Apart from the nodule-wise performance, we also assessed the algorithm for the detection of patients containing true nodules where it achieved a sensitivity of 0.95 and specificity of 1.0 over 491 scans in the test cohort. Conclusions: Our multi-institutional validated deep learning-based algorithm can aid radiologists in confirming the detection of pulmonary nodules through computed tomography (CT) scans and identifying further abnormalities and can be used as an assistive tool. This will be helpful in national lung screening programs guiding early diagnosis and appropriate management.